Cytokine-targeted therapies for asthma and COPD.

Authors:
Schleich F; Bougard N; Moermans C; Sabbe M; Louis R.

Journal:
Eur Respir Rev

Publication Year: 2023

DOI:
10.1183/16000617.0193-2022

PMCID:
PMC10113955

PMID:
37076177

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Eur Respir Rev

Abbreviation: Eur Respir Rev

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Pulmonary Medicine

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
An update on diagnosis and management of obstructive sleep apnoea in the first 2 years of life.
Polytarchou A; Moudaki A; Van de Perck E and 4 more (2024) - Transparency Score: 2/6
Clinical-imaging-pathological correlation in pulmonary hypertension associated with left heart dise…
van de Veerdonk MC; Roosma L; Trip P and 4 more (2024) - Transparency Score: 2/6
Eradication treatment for <i>Pseudomonas aeruginosa</i> infection in adults with bronchiectasis: a …
Conceição M; Shteinberg M; Goeminne P and 2 more (2024) - Transparency Score: 3/6
From treatable traits to GETomics in airway disease: moving towards clinical practice.
Papi A; Faner R; Pavord I and 6 more (2024) - Transparency Score: 3/6
Lung cancer risk and occupational pulmonary fibrosis: systematic review and meta-analysis.
Krabbe J; Steffens KM; Drießen S and 1 more (2024) - Transparency Score: 4/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflict of interest: F. Schleich has received grants or contracts from GSK, AstraZeneca and Chiesi; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from GSK, AstraZeneca, Chiesi and TEVA; and has participated on a Data Safety Monitoring Board or Advisory Board for GSK and AstraZeneca.: Conflict of interest: N. Bougard has nothing to disclose.: Conflict of interest: C. Moermans has nothing to disclose.: Conflict of interest: M. Sabbe has nothing to disclose.: Conflict of interest: R. Louis has received grants or contracts from GSK, AstraZeneca and Chiesi; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from GSK, AstraZeneca, Chiesi and TEVA; and has participated on a Data Safety Monitoring Board or Advisory Board for GSK and AstraZeneca."

Evidence found in paper:

"Conflict of interest: F. Schleich has received grants or contracts from GSK, AstraZeneca and Chiesi; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from GSK, AstraZeneca, Chiesi and TEVA; and has participated on a Data Safety Monitoring Board or Advisory Board for GSK and AstraZeneca. Conflict of interest: R. Louis has received grants or contracts from GSK, AstraZeneca and Chiesi; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from GSK, AstraZeneca, Chiesi and TEVA; and has participated on a Data Safety Monitoring Board or Advisory Board for GSK and AstraZeneca."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025